Eculizumab in kidney diseases

The C5 inhibitor monoclonal antibody, eculizumab, has been approved for the treatment of atypical hemolytic uremic syndrome (aHUS) and paroxysmal nocturnal hemoglobinuria (PNH); however, the efficacy and safety of this drug in treating other complement-related renal diseases has not yet been elucida...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Fatemeh Pour- (Autore), Sara Assadiasl (Autore)
Natura: Libro
Pubblicazione: Society of Diabetic Nephropathy Prevention, 2024-01-01T00:00:00Z.
Soggetti:
Accesso online:Connect to this object online.
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne!!

Accesso online

Connect to this object online.

3rd Floor Main Library

Dettagli sul posseduto da 3rd Floor Main Library
Collocazione: A1234.567
Copia 1 Disponibile